86 results about "Erythrocytes membrane" patented technology

The invention provides a method for preserving the activity of a human cell membrane blood group antigen, which comprises the steps of: preparing an erythrocyte membrane blood group antigen extract, and then coating the prepared erythrocyte membrane blood group antigen on a solid microsphere so as to replace a fresh erythrocyte to be used for detecting a blood group antibody in a sample.

A red cell membrane antigen magnetic bead kit and an application in blood type antibody test belong to the biological technical field, for using red cell membrane antigen magnetic beads to prepare a kit and provide the application in blood type antibody test. The kit comprises red cell membrane antigen magnetic beads, a U-shaped reaction plate of 96 holes and a red cell membrane antigen magnetic bead diluent. The invention has the advantages that the red cell membrane antigen magnetic beads have long storage period, thus is beneficial for the storage of red cell rare antigens.

The invention discloses a reverse typing colloidal gold kit for ABO blood groups and a preparation method thereof. The reverse typing colloidal gold kit for the ABO blood groups comprises a reacting plate, erythrocyte membrane antigen gold particles and a basic solution, wherein 3N reaction holes are formed in the reacting plate and are respectively used for placing A erythrocyte membrane antigen gold particles and a basic solution, B erythrocyte membrane antigen gold particles and a basic solution, and O erythrocyte membrane antigen gold particles and a basic solution; the reaction holes are of circular structures, the bottoms of the holes are smooth and U-shaped; and sealing covers are arranged on the reaction holes. The kit also can be a dry kit; and the erythrocyte membrane antigen gold particles and the basic solution are dried on the reaction holes. According to the reverse typing colloidal gold kit for the ABO blood groups and the preparation method, erythrocyte membrane blood group antigen extracts are prepared and then marked with the colloid gold, and thereby the problem that the fresh erythrocyte just can be stored in a short period can be solved. The kit has the shelf life not less than 12 months at 2 to 20 DEG C, and has the advantages of being high in sensitivity, convenient to use, and relatively low in cost, and identifying the results easily.

The invention relates to a method for trace, fast and accurate detection of human erythrocyte antigens and antibodies in serum. Tiny known antibodies for resisting erythrocyte antigens are allocated on a trace detection board by the principle of immunohematology, and tiny unknown erythrocytes to be detected are added for detecting the antigens at the surface of the erythrocyte membrane; or the erythrocytes of the tiny known erythrocyte antigens are added into the tiny unknown serum to be detected, so as to detect the antibody for resisting erythrocyte membrane surface antigens in human blood to be detected. The reaction characteristic is erythrocyte aggregation; if the aggregation exists, the reaction is a positive reaction, and otherwise the reaction is a negative reaction; and a centrifugal machine, a spectrophotometer, a microscope and a computer program are cooperated, so that the erythrocyte antigens and antibodies in serum can be detected fast, accurately and automatically. The use of the trace detection board kit prepared by the method in medical field can greatly improve the safety, efficiency and accuracy of clinical erythrocyte matching, reduce the detection expenses, and promote the development of clinical blood application.

The invention provides a bionic binary cooperative nano-carrier as well as a preparation method and an application thereof. The bionic binary cooperative nano-carrier comprises an erythrocyte membrane, glucose oxidase, iron-supporting ferritin nano-particles and a photosensitizer, wherein the glucose oxidase and the iron-supporting ferritin nano-particles are coated with the erythrocyte membrane,and the photosensitizer is embedded into the surface of the erythrocyte membrane or entrapped by the erythrocyte membrane. Chain stimulative responsibility coordination of tumor hunger therapy and chemical kinetic therapy is realized, two enzymes are conveyed to a target site of an organism with the carrier on the basis of biocompatibility of the erythrocyte membrane and tumor targeting of targeting molecules, accurate administration is realized by membrane rupture based on 808 nm near-infrared light illumination in the tumors, the problem of drug resistance is solved effectively, furthermore,systemic toxicity caused by drug application is remarkably reduced, and damage to other normal tissue in an in-vivo circulation process is prevented effectively. The invention further provides the preparation method of the bionic binary cooperative nano-carrier. The bionic binary cooperative nano-carrier and the preparation method have good application prospect.

The invention discloses a preparation method and an application of an erythrocyte membrane-coated acid-sensitive polymer prodrug nano drug delivery system, wherein the polymer is formed by connecting sodium polyglutamate and carbocisteine through a peptide bond and then is bonded with an anti-cancer drug taxol to form the polymer prodrug; and the polymer prodrug is coated by an erythrocyte membrane to obtain an erythrocyte membrane-coated acid-sensitive polymer drug delivery system. The drug delivery system has the following characteristics that the particle size is about 100nm, and the shape is a sphere; the drug delivery system is relatively stable in a phosphate buffer and serum; the drug release character is relatively good in an acid environment; the toxicity is obviously reduced in cell experiments; the ingestion of the system by macrophage is obviously reduced; without destructive effect on erythrocyte, the system can be applied to intravenous injection; the circulating time of the system in blood is remarkably longer than that of polymer; and the system has an obvious inhibiting effect on the tumor growth of lung cancer.

The invention provides a nano catalyst for tumor treatment, and a preparation method and application thereof. The nano catalyst provided by the invention comprises an erythrocyte membrane, and a composite nano enzyme and a photosensitizer which are coated in the erythrocyte membrane, wherein the composite nano enzyme comprises glucose oxidase and iron nanoparticles which are coated in an inner cavity of the glucose oxidase. The nano catalyst is preferentially accumulated at a target tumor site through targeted biomimetic delivery, and release of the composite nano enzyme is realized under irradiation of near infrared light. Based on high glucose uptake and a weakly acidic environment at the tumor site, glucose oxidase converts glucose into H2O2, induces iron nano particles to start an in-situ Fenton reaction, generates hydroxyl free radicals after sequential catalysis, induces tumor cells to be subjected to oxidative damage, and further kills the tumor cells. The nano catalyst not onlycan realize high-efficiency loading of the catalyst, but also can effectively prolong in-vivo circulation time, so that accurate and sustained release on a tumor focus part is realized, and a new thought and platform are provided for tumor treatment.

The invention belongs to the technical field of pharmacy and particularly relates to an erythrocyte membrane-encapsulated tetrandrine PLGA nanoparticle and a preparation method and application thereof. The nanoparticle structurally includes an erythrocyte membrane, PLGA and tetrandrine, the tetrandrine is combined with PLGA to form a tetrandrine-PLGA nanocore, and the erythrocyte membrane is encapsulated outside the tetrandrine-PLGA nanocore. The preparation method is simple and efficient. The nano preparation improves the biocompatibility of a whole drug delivery system, long circulation andsustained release of the tetrandrine in the human body are achieved, toxic and side effects caused by too high blood medicine peak concentration of common injections are avoided, and the nanoparticlehas a good application prospect.

The invention relates to a preparation method and application of an ultrasonic control type anti-tumor drug delivery system. The problems that existing tumor treatment drugs are low in drug loading capacity, are leaked when delivered, are low in tumor response sensitivity, slow in release and prone to causing drug resistance, and can not be controlled in vitro are solved effectively. The ultrasonic control type anti-tumor drug delivery system is established with hollow mesoporous titanium dioxide as the base body by being internally loaded with perfluorohexane and drug bleomycin, wrapped by an endogenous biological membrane-erythrocyte membrane and modified by tumor homing peptides; a nanoscale particle size distribution drug delivery system is prepared with hollow mesoporous titanium dioxide as the base body by being internally loaded with perfluorohexane and model drug bleomycin, wrapping surfaces of hollow mesoporous titanium dioxide by RBC, and being wrapped by an endogenous biological membrane-erythrocyte membrane; a tumor drug delivery system with a remote ultrasonic control function is established by modifying tumor homing peptide NGR tail ends with diacyl lipid.

The invention discloses preparation and an application of a light-triggered erythrocyte membrane wrapped NO nano bionic donor material. The method comprises the following steps: (1) synthesizing a sulfhydrylated mesoporous silica wrapped polydopamine nanoparticle, (2) preparing a dual-load polydopamine (PDA) @ mesoporous silica nanoparticle, (3) preparing a target marked erythrocyte membrane, and(4) preparing a target molecular marked erythrocyte membrane wrapped dual-load polydopamine @ mesoporous silica nanoparticle. The PDA@mSiO2 nanoparticle with good photothermal conversion performance is successfully integrated in an NO bionic nanoparticle structure; a cell membrane can be ablated to effectively release a loaded medicine under stimulation of near infrared light; at the same time, amore obvious killing effect can be caused on tumor cells; and therefore, a combined application of various treatment means is achieved.

The invention provides a bionic nanometer erythrocyte genophore and a preparation method and application thereof. The bionic nanometer erythrocyte genophore comprises an erythrocyte membrane and a kernel which is wrapped by the erythrocyte membrane and can achieve charge reversal. The invention further the preparation method of the bionic nanometer erythrocyte genophore. The method comprises the steps that the genophore which can achieve charge reversal is synthesized through an amide reaction; then, the kernel of the genophore which can achieve charge reversal is wrapped by the erythrocyte membrane through an extrusion method. According to the bionic nanometer erythrocyte genophore, a biological membrane wrapping treatment gene is applied to disease treatment for the first time, the electronegativity of the kernel can be guaranteed, the gene is successfully wrapped by the erythrocyte membrane, long circulation of gene medicine in vivo is achieved, and the charge reversal can be achieved under the focus microenvironment, and accordingly nucleic acid medicine is released. Meanwhile, the genophore is free of cytotoxicity, non-toxic metabolism in vivo can be completed, the brand-new,safe and efficient genophore is provided for gene treatment, and the genophore has wide application prospects.

The invention relates to a casset based on solid-phase type quick blood grouping and a grouping method. The casset comprises a casset body, a sample groove, an antibody groove and a gold mark groove,wherein the sample groove is arranged in the middle part of the casset body; the antibody groove is arranged at one side of the sample groove; the gold mark groove is arranged at the other side of thesample groove; a monoclonal antibody is arranged in the antibody groove; a gold mark erythrocyte membrane antigen is arranged in the gold mark groove; an upper water absorbing paper is arranged between the sample groove and the antibody groove; a blood filtering membrane is arranged between the sample groove and the gold mark groove; a lower water absorbing paper is arranged under the blood filtering membrane. The casset has the advantages that the anti-A, anti-B and anti-D specific monoclonal antibodies are used as positive typing reagents of A, B and O blood groups, the A, B and O blood group antigens (gold mark antigens) marked with the specific erythrocyte membranes are used as reverse typing immune colloidal gold reagents, and the positive and reverse typing reagents are respectivelyarranged on the casset body; the operation is simple and quick, the carrying is convenient, the accuracy is high, the casset is suitable for the condition that the positive and reverse typing reagents of the blood group typing reagent are simultaneously placed into a blasting ball at mobile blood collection sites and during emergency blood transfusion.

The invention relates to a preparation method of a targeted long-circulation nano-drug carrier for photo-thermal synergistic chemotherapy. The invention relates to a preparation method of a targeted long-circulation nano-drug carrier for photo-thermal synergistic chemotherapy. The preparation method comprises the following steps: (1) preparing mesoporous silica; (2) coating the mesoporous silica with polydopamine; (3) loading an anti-cancer drug; (4) modifying the erythrocyte membrane by adopting biotin; (5) wrapping the mesoporous silica loaded with the anti-cancer drug by using the biotin-modified erythrocyte membrane. According to the invention, local photo-thermal / chemotherapy synergistic treatment of cancer tissues is realized through the PDA coating, so the treatment efficiency is improved; through wrapping of the erythrocyte membrane, the synthesized nanoparticles can effectively avoid a biological barrier, blood circulation of the whole body is carried out, and efficient accumulation of the nanoparticles in tumors is realized; the active targeting is carried out by modifying biotin, so the aggregation of the drug carrier at a tumor part is further improved, the biocompatibility of the drug carrier is greatly improved, and the circulation time of the drug carrier in a human body is greatly prolonged.

The invention belongs to the technical field of biologics, relates to bacterial anti-toxin treatment medicines and in particular relates to a nano medicine system with a bacterial pore-forming toxin adsorption capability and application of the nano medicine system. According to the nano medicine system, an erythrocyte membrane and a phospholipid membrane are fused to prepare an erythrocyte membrane heterozygosis lipidosome by using an extrusion membrane-through method, a high-pressure homogenization method or a microjet method, and an anti-bacterial antibiotic is further prepared; and by adsorbing pore-forming toxins of bacteria to the surface of a nano medicine, the nano medicine neutralizes toxicity of the toxins to achieve anti-toxin treatment of the bacteria, and thus the effect of anti-bacterium infection treatment, particularly drug-resistant bacterium infection treatment, can be improved. The invention provides a novel interference strategy for anti-bacterium infection for clinical practice.

The invention provides a freeze-drying protection liquid of an erythrocyte membrane fragment. The protection solution is prepared from 10-20 mM of glucose, 6-12 mM of lactose, 121-141 mM of trehalose, 29-39 mM of NaCl, 4.3-5.3 mM of KCl, 0.115-0.125 mM of KH2PO4 and 0.6-1.2 mM of Na2HPO4. The invention also provides a method for preparing a freeze-dried erythrocyte membrane fragment by using the freeze-drying protection liquid. The erythrocyte membrane fragment freeze-drying protection liquid and the freeze-drying method provided by the invention can be used for preparing the freeze-dried erythrocyte membrane fragment, and the freeze-dried erythrocyte membrane fragment can be used for blood type detection and are beneficial to standardization of a reverse typing process.

The invention discloses a preparation method and an application of a nanocomposite with functional molecules coated with an erythrocyte membrane. The nanocomposite comprises an erythrocyte membrane and functional molecules, wherein the functional molecules are mRNA, protein and small molecule drugs. According to the invention, the modified erythrocyte is prepared, the erythrocyte membrane coated nucleic acid drug is extracted, lipid components such as erythrocyte membrane phospholipid can make a functional drug carrier efficiently target the spleen, and the drug is delivered into the spleen or liver cells and released to play a therapeutic role; in addition, the cell membrane improves the in-vivo circulation stability and the intracellular delivery efficiency of the functional medicine. The nanocomposite is simple in preparation and extraction method, suitable for large-scale synthesis and preparation, mild in preparation condition, high in efficiency, uniform in particle size, good in dispersity, good in targeting capacity, high in biocompatibility and efficient and stable in intracellular delivery efficiency.

The invention belongs to the technical field of biological medicines, and particularly relates to a novel kidney-targeted nano drug delivery system with biomimetic modification of an erythrocyte membrane as well as a preparation method and application of the novel kidney-targeted nano drug delivery system. According to the application, polylactic acid-glycolic acid copolymer (PLGA) is taken as a carrier material, prednisolone acetate (PA) is taken as a model drug, and a novel bionic nano drug delivery system (RBC-PA-NPs) with kidney targeting is constructed by utilizing a strategy of coating an erythrocyte membrane on the surface. The drug delivery system combines the biocompatibility of the erythrocyte membrane and the targeting property of the nanoparticles, so that the kidney targeting property of PA is improved, and the glomerulonephritis is treated more effectively. Therefore, evaluation is carried out from the aspects of a preparation process, physicochemical properties, cytotoxicity and uptake, in-vivo targeting and the like of the drug delivery system.

The invention relates to a microorganism feed additive capable of protecting pig livers and a preparation method of the microorganism feed additive. All strains adopted by the microorganism feed additive are screened out from intestinal tracts of animals, and a strain compound culturing method is adopted, so that an antagonism mechanism of the strains is avoided, and fermented products are optimized; and in the whole production technology, beneficial microorganisms are furthest maximized, and a main fermented product namely glutathione is wholly recovered from intracellular and extracellular positions. According to the microorganism feed additive and the preparation method thereof disclosed by the invention, oxygen free radicals can be effectively eliminated, so that the stability of liver cell membranes is improved, the activity of liver enzymes is promoted, the absorption of iron can also be promoted, the integrity of red cell membranes can be maintained, the biosynthesis of DNA is maintained, the normal growth of cells is maintained, and cell immunity is maintained; as a micro-ecologic preparation, the microorganism feed additive can effectively promote the digestion and the absorption of the feed by the animals, the lean meat percentage is increased, toxin disoperation can be alleviated, the feed conversion rate is increased, and the production capacity of bred animals is improved.

The invention provides a bionic nano-carrier with dual functions of oxidation and anti-oxidation, and a preparation method and an application thereof. The bionic nano-carrier comprises an erythrocytemembrane and an organic-metal framework coated in the erythrocyte membrane, and the organic-metal framework is loaded with functionalized SOD enzyme and beta-lapaquone. After the bionic nano-carrier reaches the acidic environment of tumor cells, metal-ligand bonds in the MOF are hydrolyzed to generate protonated ligands to destroy the erythrocyte membrane and release the enzyme and drug; the beta-lapafenone is catalyzed by quinone oxidoreductase 1 highly expressed by tumor cells to generate a large number of superoxide anions, and is catalyzed by the SOD enzyme to generate hydrogen peroxide, and iron ions in the SOD enzyme catalyze the hydrogen peroxide through a Fenton reaction to generate hydroxyl radicals in order to kill the tumor cells. The bionic nano-carrier provided by the invention does not generate drug resistance through enzyme treatment, can significantly reduce the systemic toxicity caused by drug application, and has extremely high clinical application prospects.

The invention discloses an erythrocyte treating, eluting and diffusing kit and provides a method for dissociating IgG antibody sensitized on an erythrocyte membrane and application of the method. The erythrocyte treating, eluting and diffusing kit treats erythrocyte sensitized by the IgG antibody to obtain diffusion liquid containing antibody and negative erythrocyte in direct antiglobulin test (DAT), the diffusion liquid containing antibody and the negative erythrocyte in direct antiglobulin test not only can be used for classical indirect antiglobulin test and also can be used for detecting erythrocyte antigen or antibody in the diffusion liquid through a microcolumn gel card. The kit comprises the following three reagents including a solution I, a solution II and a solution III, wherein the solution I and the solution II are mixed to prepare eluant according to volume ratio of (1:1)-(1:8), and the solution III is used for judging reaction endpoint. The diffusing kit which is convenient to use and stable om quality and a preparation method of the kit are provided.

Intact erythrocytes with selected and often elevated levels of hemoglobin A1c (HbA1c) for use as quality controls for HbA1c assays and assay instruments are prepared by hypotonic dialysis of erythrocytes from a healthy mammal to permeabilize the erythrocyte membranes, infusion of the permeabilized erythrocytes with hemoglobin A1c, and de-permeabilization of the infused erythrocytes. Quality controls of essentially any level of HbA1c can be prepared in this manner and once prepared will be useful for monitoring the entire assay procedure, including the lysis of the erythrocytes in a typical sample.

The invention discloses polysubstituted thieno[2,3-b]pyridine derivatives, and a preparation method and an application thereof. The structural formula of the derivatives are represented by formula I shown in the description. A compound for inhibiting a urea transporter is screened by using an erythrocyte model. Experimental results show that the compounds (represented by formula I-1) can inhibit the permeation of a urea transporter UT-B mediated erythrocyte membrane to urea, and the effect of the compounds has a dose-dependent relationship; the compounds represented by the formula I-1 have nocytotoxic effect on MDCK cells within an effective dose range, so the effect of the compounds represented by the formula I-1 on inhibiting cell permeation urea is irrelevant to the cytotoxicity of thecompounds; the inhibition effect of the compounds represented by the formula I-1 on the urea transporter UT-B is gradually enhanced; the inhibiting effect of the compounds represented by the formulaI-1 on the UT-B is reversible; and in-vivo test results show that the compounds represented by the formula I-1 can significantly increase the urination volume of rats, reduce the concentration of ureain rat urine and reduce the osmotic pressure, so that the compounds represented by the formula I-1 generate a urea selective diuresis effect in vivo.

The invention discloses an application of an erythrocyte bionic nanomaterial of PCM polypeptide combined with KALA polypeptide in treatment of cardiovascular diseases, and also discloses a preparation method of the erythrocyte bionic nanomaterial. The method comprises the following steps: obtaining a proper quantity of PCM, performing combining with KALA, and performing fusing into a fusion peptide; enabling the fusion peptide to be subjected to amino acid protection operation treatment, so as to obtain PCM / KALA polypeptide; enabling the PCM / KALA polypeptide to be combined on the surface of an erythrocyte membrane (RBCM); and enabling the PCM / KALA polypeptide combined with the erythrocyte membrane to pass through a polycarbonate membrane with the pore diameter of 400nm by utilizing an Extrusion method, so as to construct the RBCM-PCM / KALA erythrocyte bionic nanoparticles. The erythrocyte bionic nanomaterial prepared by the method can be efficiently and rapidly introduced into cells without depending on concentration, and compared with the prior art, the erythrocyte bionic nanomaterial also has a heart enrichment function.

The invention discloses an application of erythrocyte and activated platelet membranes as carriers in preparation of thrombus treatment drugs, and relates to the technical field of medical thrombus treatment. The invention firstly provides an application of an erythrocyte membrane and an activated platelet membrane as carriers in preparation of thrombolytic drugs, and secondly, provides a composition for inhibiting and / or dissolving thrombus, comprising a thrombolytic drug, mesoporous silicon, an erythrocyte membrane, an activated platelet membrane and derivative membranes under various physiological and pathological conditions. Experimental research finds that a drug delivery system coated with an erythrocyte membrane and an activated platelet membrane has an obvious thrombolytic effect.The composition for inhibiting and / or dissolving thrombus is obtained by physically adsorbing thrombolytic drugs by utilizing mesoporous silicon, and coating the mesoporous silicon with an erythrocytemembrane and an activated platelet membrane. The thrombolytic drug is carried by the biological membranes, so that the targeting property and the enrichment degree of thrombus can be enhanced, the circulation time is remarkably prolonged, the bleeding risk is reduced, and a good thrombolytic effect is achieved.

The invention relates to the field of nano medicine and biological detoxification, in particular to a cyclic gamma-polyglutamic acid modified poly-N-isopropylacrylamide hydrogel loaded nano sponge detoxification system and a preparation method thereof. PLGA nanoparticles are wrapped with erythrocyte membrane vesicae prepared from extracted erythrocyte membranes to prepare nano sponge, and cyclic gamma-polyglutamic acid modified poly-N-isopropylacrylamide hydrogel is loaded with the nano sponge to obtain the system. The prepared hydrogel of a three-dimensional network structure has good biocompatibility, can be loaded with the NS to form the detoxification system with the local toxin adsorption effect, and can be applied to the fields of biological medicines, medical auxiliary materials andthe like.

The invention relates to a magnetic nanoparticle wrapped in red blood cell membrane and its preparation method and application, specifically PEG-Fe prepared by hydrothermal method 3 o 4 Extrusion and encapsulation of targeted modified erythrocyte membrane fragments to prepare nanoparticle erythrocyte membrane-PEG-Fe with immune evasion and sensitive magnetic responsiveness 3 o 4 , can target and adsorb cancer cells sensitive to folic acid, so that it can be controlled by a magnetic field or killed by light and heat stimulation. Erythrocyte membrane‑PEG‑Fe 3 o 4 It can be effectively targeted and adsorbed to the membrane of folic acid-sensitive cancer cells, endowing cancer with magnetic responsiveness, which is conducive to the control of movement by magnetic field and killing by light and heat stimulation. Therefore, it has potential application prospects in targeted therapy and industrial promotion.

The invention relates to the use of human erythrocyte membrane during the preparation of the medicine for remedying tumors, also provides injection which embodies the use. The injection comprises human erythrocyte membrane albumen and buffer solution. The concentration of the human erythrocyte membrane albumen in the buffer solution is 10mg / ml-30mg / ml. The buffer solution is PBS or physiological saline solution. The injection of the invention can cure various solid tumors.

The invention relates to a preparation method of a multi-stage bionic nano-drug carrier with targeted long circulation. The invention relates to a preparation method of a multi-stage bionic nano-drug carrier with targeted long circulation. The preparation method comprises the following steps: (1) preparing mesoporous silica; (2) loading an anti-cancer drug to the mesoporous silica; (3) modifying an erythrocyte membrane by adopting biotin; and (4) wrapping the mesoporous silica loaded with the anti-cancer drug by using the biotin-modified erythrocyte membrane. According to a technical scheme in the invention, synthesized nanoparticles can effectively avoid a biological barrier through wrapping of the erythrocyte membrane and enter blood circulation of the whole body, and efficient accumulation of the nanoparticles in tumors is achieved; and active targeting is carried out by modifying biotin, so the aggregation of a drug carrier in a tumor part is further improved, the biocompatibility of the drug carrier is greatly improved, the circulation time of the drug carrier in a human body is greatly prolonged, the aggregation effect of the drug carrier in a tumor area is improved through the targeting effect, and the drug carrier can be used for delivering drugs in cancer cells.

The invention discloses erythrocyte membrane coated drug-loaded nanoparticles / probes and application thereof in diagnosis and treatment of glioblastoma. The erythrocyte membrane coated drug-loaded nanoparticles are obtained by coating an erythrocyte membrane of a human or animal with doxorubicin hydrochloride-loaded poly(lactic-co-glycolic acid) (PLGA). The nanoparticles obtained by the invention have the characteristics of similar particle size and shape, capability of providing a relatively stable internal environment, long circulation time in blood in an animal body, biocompatibility, high targeted accumulation content in a tumor and the like, tumor diagnosis can be realized through fluorescence imaging, and a drug can be released at a tumor part; tumor growth is inhibited in vivo, and the survival time of animals is prolonged.